Literature DB >> 6580034

Non interference by heparin with the cytostatic effect of adriamycin: an in vitro study on a human promyelocytic leukaemia cell line.

P Foa, E Cofrancesco, L Lombardi, M Colombi, E M Pogliani, E E Polli.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6580034      PMCID: PMC2011511          DOI: 10.1038/bjc.1983.258

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  9 in total

1.  Endogenous thymic factors regulating cell proliferation and analysis of their mechanism of action.

Authors:  I Blazsek; D Gaál
Journal:  Cell Tissue Kinet       Date:  1978-05

2.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.

Authors:  S J Collins; R C Gallo; R E Gallagher
Journal:  Nature       Date:  1977-11-24       Impact factor: 49.962

3.  The rationale of anticoagulants in the treatment of cancer.

Authors:  E E Cliffton; C E Grossi
Journal:  J Med       Date:  1974

4.  Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III.

Authors:  A N Teien; M Lie
Journal:  Thromb Res       Date:  1977-03       Impact factor: 3.944

5.  Heparin inhibition of the cytostatic effect of Adriamycin on cultured lymphocytes.

Authors:  W Muntean; H Gleispach; I D Mutz
Journal:  Acta Haematol       Date:  1981       Impact factor: 2.195

6.  Binding of adriamycin to sulphated mucopolysaccharides.

Authors:  M Menozzi; F Arcamone
Journal:  Biochem Biophys Res Commun       Date:  1978-01-30       Impact factor: 3.575

Review 7.  Malignancy and haemostasis.

Authors:  M B Donati; A Poggi
Journal:  Br J Haematol       Date:  1980-02       Impact factor: 6.998

8.  Antiheparin activity of Adriamycin.

Authors:  E Cofrancesco; A Vigo; E Pogliani
Journal:  Thromb Res       Date:  1980-06-01       Impact factor: 3.944

9.  Interaction between heparin and adriamycin in mice bearing the Lewis lung carcinoma.

Authors:  T Colombo; F Delaini; R Ferrari; M B Donati; M G Donelli; A Poggi
Journal:  Biomedicine       Date:  1981-12
  9 in total
  2 in total

Review 1.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

2.  Doxorubicin-heparin complex: reduction of cardiotoxicity of doxorubicin.

Authors:  Y Mizuno; T Hara; S Tachibana; K Uragoh; K Akazawa; K Ueda
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.